Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.

ABSTRACT:

SUBMITTER: Matsubara N 

PROVIDER: S-EPMC6828099 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature